GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: LY-3303560 | LY3303560
                                 
                                                         
                            Compound class: 
                                                            Antibody
                                 
                                
                                    
                                        Comment: LY3303560 is a monoclonal antibody that selectively targets tau protein aggregates [1]. It is being developed by Eli Lilly for potential to treat Alzheimer's disease. The primary epitope for LY3303560 is located in the N-terminal region of tau.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
Classification ![]()  | 
                                                    |
| Compound class | Antibody | 
International Nonproprietary Names ![]()  | 
                                                        |
| INN number | INN | 
| 11050 | zagotenemab | 
Synonyms ![]()  | 
                                                        
| LY-3303560 | LY3303560 | 
Database Links ![]()  | 
                                                        |
| GtoPdb PubChem SID | 385612231 | 
| Search PubMed clinical trials | zagotenemab | 
| Search PubMed titles | zagotenemab | 
| Search PubMed titles/abstracts | zagotenemab |